Two critically important issues in human immunodeficiency virus (HIV) therapeutics are
when to start antiretroviral therapy and how well these medications restore immunity. In this
issue of JAMA Internal Medicine, Okulicz et al1 describe a prospective cohort study of 1119
US military service persons with known seroconversion dates who were monitored for
several years. Because the dates of seroconversion were known for these individuals and
their immunologic status was well characterized, the data from this valuable cohort enable …